SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2004: 221236.
  • 2
    McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38: 14841493.
  • 3
    Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992; 327: 13421349.
  • 4
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 5
    Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002; 29(2 Suppl 6 ): 1822.
  • 6
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 7
    Ries L, Eisner M, Kosary C, et al. SEER cancer statistics review, 1975–2002, vol 2005. Bethesda: National Cancer Institute, 2005. Available at URL: http://seer.cancer.gov/csr/1975_2002/ [based on the November 2004 SEER data submission, posted to the SEER web site 2005]. Accessed December 14, 2005.
  • 8
    Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004; 22: 43024311.
  • 9
    Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 26332641.
  • 10
    Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987; 257: 27662770.
  • 11
    Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732748.
  • 12
    Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349357.
  • 13
    Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002; 20: 173178.
  • 14
    Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003; 21: 34093414.
  • 15
    Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40(8 Suppl ): IV-1925.
  • 16
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373383.
  • 17
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40(8 Suppl ): IV-55IV-61.
  • 18
    Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002; 40: 201211.
  • 19
    D'Agostino RBJr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17: 22652281.
  • 20
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127(8 Pt 2): 757763.
  • 21
    Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968; 24: 295313.
  • 22
    Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998; 54: 948963.
  • 23
    Mitra N, Heitjan DF. Sensitivity of the Hazard Ratio to Non-Ignorable Treatment Assignment in an Observational Study. Upenn Biostatistics Working Papers. Paper 5, 2006. The Berkeley Electronic Press. Available at: http://biostats/bepress.com/upennbiostat/papers/arts [accessed May 24, 2006].
  • 24
    Cheson BD. CHOP plus rituximab—balancing facts and opinion. N Engl J Med. 2002; 346: 280292.
  • 25
    Grann A, Grann VR. The case for randomized trials in cancer treatment: new is not always better. JAMA. 2005; 293: 10011003.
  • 26
    Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995; 13: 25302539.
  • 27
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23: 41174126.
  • 28
    Miller TP, Dana BW, Weick JK, et al. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1988; 25(2 Suppl 2 ): 1722.
  • 29
    Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CAJr. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987; 24(2 Suppl 1 ): 2125.
  • 30
    Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002; 40(8 Suppl ): IV-7581.
  • 31
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 19371947.
  • 32
    Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106: 31833190.
  • 33
    Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005; 23: 510517.
  • 34
    Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002; 20: 26432650.
  • 35
    Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004; 94: 540549.
  • 36
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology – v.2.2006 Non-Hodgkin's Lymphoma. Available at: http://www.nccn.org/professionals/physicians_gls/PDF/nhl.pdf [accessed May 24, 2006].